FULC vs. EWTX, SDGR, BHVN, ETNB, ANIP, JANX, EVO, MESO, VERA, and OCUL
Should you be buying Fulcrum Therapeutics stock or one of its competitors? The main competitors of Fulcrum Therapeutics include Edgewise Therapeutics (EWTX), Schrodinger (SDGR), Biohaven (BHVN), 89BIO (ETNB), ANI Pharmaceuticals (ANIP), Janux Therapeutics (JANX), Evotec (EVO), Mesoblast (MESO), Vera Therapeutics (VERA), and Ocular Therapeutix (OCUL). These companies are all part of the "pharmaceutical products" industry.
Fulcrum Therapeutics vs. Its Competitors
Fulcrum Therapeutics (NASDAQ:FULC) and Edgewise Therapeutics (NASDAQ:EWTX) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, media sentiment, valuation, profitability and risk.
Fulcrum Therapeutics has a beta of 2.37, meaning that its share price is 137% more volatile than the S&P 500. Comparatively, Edgewise Therapeutics has a beta of 0.25, meaning that its share price is 75% less volatile than the S&P 500.
In the previous week, Edgewise Therapeutics had 17 more articles in the media than Fulcrum Therapeutics. MarketBeat recorded 19 mentions for Edgewise Therapeutics and 2 mentions for Fulcrum Therapeutics. Edgewise Therapeutics' average media sentiment score of 0.50 beat Fulcrum Therapeutics' score of -0.32 indicating that Edgewise Therapeutics is being referred to more favorably in the news media.
Fulcrum Therapeutics has higher revenue and earnings than Edgewise Therapeutics. Fulcrum Therapeutics is trading at a lower price-to-earnings ratio than Edgewise Therapeutics, indicating that it is currently the more affordable of the two stocks.
Fulcrum Therapeutics currently has a consensus price target of $6.29, indicating a potential downside of 9.10%. Edgewise Therapeutics has a consensus price target of $40.00, indicating a potential upside of 208.76%. Given Edgewise Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Edgewise Therapeutics is more favorable than Fulcrum Therapeutics.
Fulcrum Therapeutics' return on equity of -0.20% beat Edgewise Therapeutics' return on equity.
89.8% of Fulcrum Therapeutics shares are held by institutional investors. 7.0% of Fulcrum Therapeutics shares are held by company insiders. Comparatively, 23.2% of Edgewise Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Summary
Fulcrum Therapeutics beats Edgewise Therapeutics on 8 of the 15 factors compared between the two stocks.
Get Fulcrum Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for FULC and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding FULC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Fulcrum Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:FULC) was last updated on 7/3/2025 by MarketBeat.com Staff